Rational Drug Design of Small Molecule Anticancer Agents: Preclinical Discovery

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Unknown venue

• Publication date

  2007-10-15

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1002/9780470025079.CHAP96.PUB2
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Pharmacodynamic biomarkers for molecular cancer therapeutics.

  2007cited by this paper
• Identification of Inhibitors of the Kinase Activity of Oncogenic V600EBRAF in an Enzyme Cascade High-Throughput Screen

  2006cited by this paper
• Inhibitors of the HSP90 molecular chaperone: attacking the master regulator in cancer.

  2006cited by this paper
• Selective kinase inhibition by exploiting differential pathway sensitivity.

  2006cited by this paper
• Discovery of protein phosphatase inhibitor classes by biology-oriented synthesis.

  2006cited by this paper
• Use of three-dimensional tissue cultures to model extravascular transport and predict in vivo activity of hypoxia-targeted anticancer drugs.

  2006cited by this paper
• RNAi-based screening of the human kinome identifies Akt-cooperating kinases: a new approach to designing efficacious multitargeted kinase inhibitors

  2006cited by this paper
• Cancer Biomarkers—An Invitation to the Table

  2006influential reference
• Spotlight on molecular profiling: “Integromic” analysis of the NCI-60 cancer cell lines

  2006cited by this paper
• Hexachlorophene Inhibits Wnt/β-Catenin Pathway by Promoting Siah-Mediated β-Catenin Degradation

  2006cited by this paper
• Cancer: Off by a whisker

  2006cited by this paper
• Validating cancer drug targets

  2006cited by this paper
• BRAF mutation predicts sensitivity to MEK inhibition

  2006cited by this paper
• Potentiation of paclitaxel activity by the HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin in human ovarian carcinoma cell lines with high levels of activated AKT

  2006cited by this paper
• Rational design of inhibitors that bind to inactive kinase conformations

  2006cited by this paper
• hERG potassium channels and cardiac arrhythmia

  2006cited by this paper
• Preclinical pharmacokinetics and metabolism of a novel diaryl pyrazole resorcinol series of heat shock protein 90 inhibitors

  2006cited by this paper
• Design and development of signal transduction inhibitors for cancer treatment: Experience and challenges with kinase targets

  2006cited by this paper
• The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants.

  2006cited by this paper
• Inhibitors of the HSP90 molecular chaperone: current status.

  2006cited by this paper
• Drugging the PI3 kinome

  2006cited by this paper
• A Pharmacological Map of the PI3-K Family Defines a Role for p110α in Insulin Signaling

  2006cited by this paper
• New approaches to molecular cancer therapeutics

  2006cited by this paper
• The New Era in Cancer Research

  2006cited by this paper
• Systems biology and combination therapy in the quest for clinical efficacy

  2006cited by this paper
• Tools for kinetic modeling of biochemical networks

  2006cited by this paper
• Contributions of human tumor xenografts to anticancer drug development.

  2006cited by this paper
• A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma.

  2006cited by this paper
• Genetically engineered models have advantages over xenografts for preclinical studies.

  2006cited by this paper
• Minimally invasive pharmacokinetic and pharmacodynamic technologies in hypothesis-testing clinical trials of innovative therapies.

  2006cited by this paper
• Sensitive mutation detection in heterogeneous cancer specimens by massively parallel picoliter reactor sequencing

  2006cited by this paper
• Stem cells and cancer: two faces of eve.

  2006cited by this paper
• Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer

  2006cited by this paper
• Substrate and inhibitor specificity of class 1 and class 2 histone deacetylases.

  2006cited by this paper
• Identification of chemically diverse Chk1 inhibitors by receptor-based virtual screening.

  2006cited by this paper
• Discovery and development of pyrazole-scaffold Hsp90 inhibitors.

  2006cited by this paper
• The Akt/PKB family of protein kinases: a review of small molecule inhibitors and progress towards target validation.

  2005cited by this paper
• A family of phosphodiesterase inhibitors discovered by cocrystallography and scaffold-based drug design

  2005cited by this paper
• Characterisation of kinase-selective inhibitors by chemical proteomics.

  2005cited by this paper
• Identification of novel p38alpha MAP kinase inhibitors using fragment-based lead generation.

  2005cited by this paper
• Oncogenes come of age.

  2005cited by this paper
• Preclinical and clinical development of the oral multikinase inhibitor sorafenib in cancer treatment.

  2005cited by this paper
• Features of selective kinase inhibitors.

  2005cited by this paper
• Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma

  2005cited by this paper
• Exploring the sounds of silence: RNAi-mediated gene silencing for target identification and validation.

  2005cited by this paper
• Molecular mechanisms of drug resistance

  2005cited by this paper
• Target discovery in small-molecule cell-based screens by in situ proteome reactivity profiling

  2005cited by this paper
• Back to the drawing board on immunohistochemistry and predictive factors.

  2005cited by this paper
• An inhibitor of Bcl-2 family proteins induces regression of solid tumours

  2005cited by this paper
• Diversity-oriented synthesis: exploring the intersections between chemistry and biology

  2005cited by this paper
• Genomics and the second golden era of cancer drug development.

  2005cited by this paper
• Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

  2005cited by this paper
• Targeting protein–protein interactions for cancer therapy

  2005cited by this paper
• Keynote review: in vitro safety pharmacology profiling: an essential tool for successful drug development.

  2005cited by this paper
• A genome-wide overexpression screen in yeast for small-molecule target identification.

  2005cited by this paper
• EGFR mutation and resistance of non-small-cell lung cancer to gefitinib.

  2005cited by this paper
• Target‐Family‐Oriented Focused Libraries for Kinases—Conceptual Design Aspects and Commercial Availability

  2005cited by this paper
• Promoting apoptosis as a strategy for cancer drug discovery

  2005cited by this paper
• Compound selection and filtering in library design

  2005cited by this paper
• Design and synthesis of protein superfamily-targeted chemical libraries for lead identification and optimization.

  2005cited by this paper
• Predicting drug-drug interactions in drug discovery: where are we now and where are we going?

  2005cited by this paper
• Drugging the cancer kinome: progress and challenges in developing personalized molecular cancer therapeutics.

  2005cited by this paper
• Identification of novel small molecule inhibitors of hypoxia-inducible factor-1 that differentially block hypoxia-inducible factor-1 activity and hypoxia-inducible factor-1alpha induction in response to hypoxic stress and growth factors.

  2005cited by this paper
• Drug Insight: histone deacetylase inhibitors—development of the new targeted anticancer agent suberoylanilide hydroxamic acid

  2005cited by this paper
• Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain

  2005cited by this paper
• Finding the target after screening the phenotype.

  2005cited by this paper
• High throughput screening for protein kinase inhibitors.

  2005cited by this paper
• Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining?

  2005cited by this paper
• A small molecule–kinase interaction map for clinical kinase inhibitors

  2005cited by this paper
• Novel, potent small-molecule inhibitors of the molecular chaperone Hsp90 discovered through structure-based design.

  2005cited by this paper
• Components of successful lead generation.

  2005cited by this paper
• Pharmacokinetic-Pharmacodynamic Relationships for the Heat Shock Protein 90 Molecular Chaperone Inhibitor 17-Allylamino , 17-Demethoxygeldanamycin in Human Ovarian Cancer

  2005cited by this paper
• Identification of Akt Pathway Inhibitors Using Redistribution Screening on the FLIPR and the IN Cell 3000 Analyzer

  2005cited by this paper
• The identification, synthesis, protein crystal structure and in vitro biochemical evaluation of a new 3,4-diarylpyrazole class of Hsp90 inhibitors.

  2005cited by this paper
• Structure-activity relationships in purine-based inhibitor binding to HSP90 isoforms.

  2004cited by this paper
• Fragment-based lead discovery

  2004cited by this paper
• Navigating chemical space for biology and medicine

  2004cited by this paper
• A census of human cancer genes

  2004cited by this paper
• Biopharmaceutics Classification by High Throughput Solubility Assay and PAMPA

  2004cited by this paper
• Ligand efficiency: a useful metric for lead selection.

  2004cited by this paper
• Telomerase Inhibition and Cell Growth Arrest After Telomestatin Treatment in Multiple Myeloma

  2004cited by this paper
• Structural snapshots of human HDAC8 provide insights into the class I histone deacetylases.

  2004cited by this paper
• Gene expression microarray technologies in the development of new therapeutic agents.

  2004cited by this paper
• Phase I trial design for solid tumor studies of targeted, non-cytotoxic agents: theory and practice.

  2004cited by this paper
• Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition

  2004cited by this paper
• Protein Kinase Inhibitors: Insights into Drug Design from Structure

  2004cited by this paper
• In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2

  2004cited by this paper
• Characteristic physical properties and structural fragments of marketed oral drugs.

  2004cited by this paper
• Identification of potent Ras signaling inhibitors by pathway-selective phenotype-based screening.

  2004cited by this paper
• Identification of compounds with nanomolar binding affinity for checkpoint kinase-1 using knowledge-based virtual screening.

  2004cited by this paper
• Can the pharmaceutical industry reduce attrition rates?

  2004influential reference
• Complex phenotypic assays in high-throughput screening.

  2004cited by this paper
• Recent kinase and kinase inhibitor X-ray structures: mechanisms of inhibition and selectivity insights.

  2004cited by this paper
• Cassette dosing pharmacokinetics of a library of 2,6,9-trisubstituted purine cyclin-dependent kinase 2 inhibitors prepared by parallel synthesis.

  2004cited by this paper
• Overriding Imatinib Resistance with a Novel ABL Kinase Inhibitor

  2004cited by this paper
• Stuart Schreiber: biology from a chemist's perspective. Interview by Joanna Owens.

  2004cited by this paper
• Combined application of parallel artificial membrane permeability assay and Caco-2 permeability assays in drug discovery.

  2004cited by this paper
• Applications of high-throughput ADME in drug discovery.

  2004cited by this paper
• Influence of molecular flexibility and polar surface area metrics on oral bioavailability in the rat.

  2004cited by this paper
• A three-hybrid approach to scanning the proteome for targets of small molecule kinase inhibitors.

  2004cited by this paper

• Molecular insights into kaempferol derivatives as potential inhibitors for CDK2 in colon cancer: pharmacophore modeling, docking, and dynamic analysis

  2024cites this paper
• New2-((2-(2,4-dinitrophenyl)hydrazineeylidene) derivatives: design, synthesis, in silico, and in vitro anticancer studies

  2023cites this paper
• Synthesis, Structure-Activity Relationship Studies Using Density Functional Theory and in silico Molecular Docking on Substituted Benzohydrazide Derivatives

  2023cites this paper
• Design, synthesis, anticancer evaluation and molecular docking study of novel 2,4-dichlorophenoxymethyl-based derivatives linked to nitrogenous heterocyclic ring systems as potential CDK-2 inhibitors

  2022cites this paper
• Synthesis, biological evaluation and kinase profiling of novel S-benzo[4,5]thiazolo[2,3-c][1,2,4]triazole derivatives as cytotoxic agents with apoptosis-inducing activity

  2020cites this paper